Recon: GSK reviews whether shingles jab reduces dementia risk; Axsome ADHD hits goal in late-stage trial
ReconJason Scott
Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaNutritional/Natural HealthPharmaceuticalsRegulatory Intelligence/PolicyUnited States